KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Restructuring Costs: 2016-2024

Historic Restructuring Costs for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $2.4 million.

  • Amneal Pharmaceuticals' Restructuring Costs fell 16.86% to $143,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 12.90%. This contributed to the annual value of $2.4 million for FY2024, which is 34.65% up from last year.
  • Amneal Pharmaceuticals' Restructuring Costs amounted to $2.4 million in FY2024, which was up 34.65% from $1.7 million recorded in FY2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Restructuring Costs peaked at $9.0 million during FY2020, and registered a low of $1.4 million during FY2022.
  • For the 3-year period, Amneal Pharmaceuticals' Restructuring Costs averaged around $1.8 million, with its median value being $1.7 million (2023).
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Restructuring Costs slumped by 82.46% in 2022, and later surged by 34.65% in 2024.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Restructuring Costs stood at $9.0 million in 2020, then fell by 10.00% to $8.1 million in 2021, then tumbled by 82.46% to $1.4 million in 2022, then grew by 23.08% to $1.7 million in 2023, then surged by 34.65% to $2.4 million in 2024.